Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Alibaba Health Information Technology ( (HK:0241) ).
Alibaba Health Information Technology Limited has entered into a lease agreement through its subsidiary, Alibaba Health Pharmaceutical Chain, with Hangzhou Chuanfu for a 30-month lease of a production plant and ancillary facilities in Hangzhou, China. This transaction, classified as a connected transaction under the Listing Rules, involves the use of the premises as a warehouse for pharmaceutical products and medical devices, with the total rent and property management fees capped at RMB34.8 million for the lease term. The agreement will impact the company’s financial statements by recognizing the right-of-use asset, reflecting its strategic expansion in pharmaceutical logistics.
The most recent analyst rating on (HK:0241) stock is a Buy with a HK$6.50 price target. To see the full list of analyst forecasts on Alibaba Health Information Technology stock, see the HK:0241 Stock Forecast page.
More about Alibaba Health Information Technology
Alibaba Health Information Technology Limited operates within the healthcare industry, focusing on pharmaceutical distribution and health-related services. The company is a subsidiary of Alibaba Holding, which is its ultimate controlling shareholder.
Average Trading Volume: 128,360,345
Technical Sentiment Signal: Buy
Current Market Cap: HK$91.71B
See more insights into 0241 stock on TipRanks’ Stock Analysis page.